Progyny director Kevin Gordon sells $321,358 in company stock
Progyny director Kevin K. Gordon sold 11,500 shares for $321,358 at $27.94 each. The stock rose 59% in six months. Progyny reported Q2 2026 earnings of $0.55 per share on $350.51M revenue, beating estimates. Citizens raised its price target to $33. Progyny maintains full-year guidance of $1.36B-$1.385B revenue and $2.04-$2.10 EPS.
How this was made
The 30-second read
Why it matters
The insider sale adds a modest negative nuance to an otherwise positive earnings backdrop.
Market read
New insider sale amid strong earnings; limited trading impact.
What to watch
Recent strong Q2 results and raised price targets could offset the negative signal.
Background
Progyny reported strong Q2 earnings and reaffirmed full‑year guidance, while Citizens raised its price target.
Ticker impact
Director Kevin Gordon sold 11,500 shares for $321,358, a new Form 4 filing.
Potential modest dip in PGNY price over the next few days.
Sale size is modest ($321k) and likely for tax reasons, but insider disposals often weigh on sentiment.
Market effects
Minimal impact on the fertility‑benefits sector.
U.S. market only; no broader regional effect.
Low global relevance.
Counterpoint
The sale may be tax‑driven and not reflect confidence; investors could view it as a buying opportunity.
Key entities
- companyProgyny, Inc.
Provider of fertility‑benefits solutions.
- personKevin K. Gordon
Director of Progyny who sold shares.
